Here, we introduce BBO-8520, a potent, selective, orally bioavailable, direct covalent inhibitor of KRAS G12C, with dual activity against both the (OFF) and (ON) states of KRAS G12C. BBO-8520 is ...

Our study addresses the urgent need for treatment strategies for TKI-resistant gastrointestinal stromal tumors (GIST). We have identified a non-TKI compound, OPB-171775, that exhibits significant ...

Abstract. The integration of artificial intelligence (AI) in cancer research has significantly advanced radiology, pathology, and multimodal approaches, offering unprecedented capabilities in image ...

Abstract. Radiomics, the extraction of quantitative data from images, holds promise for noninvasively characterizing tumor phenotypes. Tools like LIFEx have improved the accessibility, transparency, ...

KRAS pathways are frequently upregulated in cancers bearing KRAS mutations or by other signaling modifications. Also, resistance to KRAS G12C inhibitors and other KRAS/RAF/MEK pathway drugs is ...

Abstract. Introduction: Antibody and peptide-conjugated drugs are rapidly entering the clinic for the treatment of patients with early and advanced breast cancer. These drugs are designed to achieve ...

Doxorubicin-naïve patients with metastatic soft-tissue sarcoma were enrolled in this phase Ib study. Every 21 days, subjects received ribociclib daily for 7 days followed by 3 days of no treatment ...

The FDA today granted accelerated approval to linvoseltamab (Lynozyfic, Regeneron) for adults with relapsed or refractory multiple myeloma who have already received at least four therapeutic regimens.

Homologous recombination is a high-fidelity DNA repair mechanism essential for maintaining genome stability. Impairment of this pathway, often due to BRCA1 or BRCA2 inactivation, leads to homologous ...

Chimeric antigen receptor (CAR) T-cell therapy has improved outcomes for patients with chemotherapy-resistant B-cell malignancies. However, CAR T-cell treatment of patients with solid cancers has been ...

AbstractPurpose:. Death receptor (DR)–targeted therapies offer a promising tumor cell–specific therapeutic strategy for highly malignant brain tumors, such as glioblastoma (GBM). However, whether ...

Abstract. Background: KRAS mutations are the most frequently encountered driver oncogene, involved in ~25% of all human cancers [1,2]. KRASG12D is the predominant KRAS mutation isoform, detected in ...